[1]JournalofMedicinalChemistry,2008,vol.51,p.1111-1114
Title: Quantitative high-throughput profiling of environmental chemicals and drugs that modulate farnesoid X receptor.
Journal: Scientific reports 20140101
Title: Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
Journal: Bioorganic & medicinal chemistry letters 20101101
Title: Parbendazole.
Journal: Profiles of drug substances, excipients, and related methodology 20100101
Title: Epidemiological aspects of the first outbreak of Baylisascaris procyonis larva migrans in rabbits in Japan.
Journal: The Journal of veterinary medical science 20030401
Title: In vitro susceptibilities of the AIDS-associated microsporidian Encephalitozoon intestinalis to albendazole, its sulfoxide metabolite, and 12 additional benzimidazole derivatives.
Journal: Antimicrobial agents and chemotherapy 19971201
Title: Activity of benzimidazoles against cryptosporidiosis in neonatal BALB/c mice.
Journal: The Journal of parasitology 19951001
Title: In vitro susceptibility of the opportunistic fungus Cryptococcus neoformans to anthelmintic benzimidazoles.
Journal: Antimicrobial agents and chemotherapy 19940201
Title: Lo YC, et al. Computational Cell Cycle Profiling of Cancer Cells for Prioritizing FDA-Approved Drugs with Repurposing Potential. Sci Rep. 2017 Sep 12;7(1):11261.
Title: Havercroft JC, et al. Binding of parbendazole to tubulin and its influence on microtubules in tissue-culture cells as revealed by immunofluorescence microscopy. J Cell Sci. 1981 Jun;49:195-204.
Title: Foster KE, et al. A mutant beta-tubulin confers resistance to the action of benzimidazole-carbamate microtubule inhibitors both in vivo and in vitro. Eur J Biochem. 1987 Mar 16;163(3):449-55.
